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Abstract
Aims/hypothesis We studied the physiological, metabolic
and hormonal mechanisms underlying the elevated risk of
type 2 diabetes in carriers of TCF7L2 gene.
Methods We undertook genotyping of 81 healthy young
Danish men for rs7903146 of TCF7L2 and carried out
various beta cell tests including: 24 h glucose, insulin and
glucagon profiles; OGTT; mixed meal test; IVGTT; hyper-
glycaemic clamp with co-infusion of glucagon-like peptide
(GLP)-1 or glucose-dependent insulinotropic polypeptide
(GIP); and a euglycaemic–hyperinsulinaemic clamp com-
bined with glucose tracer infusion to study hepatic and
peripheral insulin action.
Results Carriers of the T allele were characterised by
reduced 24 h insulin concentrations (p<0.05) and reduced
insulin secretion relative to glucose during a mixed meal
test (beta index: p<0.003), but not during an IVGTT. This
was further supported by reduced late-phase insulinotropic
action of GLP-1 (p=0.03) and GIP (p=0.07) during a
7 mmol/l hyperglycaemic clamp. Secretion of GLP-1 and
GIP during the mixed meal test was normal. Despite
elevated hepatic glucose production, carriers of the T allele
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had significantly reduced 24 h glucagon concentrations
(p<0.02) suggesting altered alpha cell function.
Conclusions/interpretation Elevated hepatic glucose pro-
duction and reduced insulinotropic effect of incretin
hormones contribute to an increased risk of type 2 diabetes
in carriers of the rs7903146 risk T allele of TCF7L2.
Keywords Genetics . Glucagon . Hepatic glucose
production . Incretin hormones . Insulin secretion . TCF7L2 .
Type 2 diabetes
Abbreviations
EGP Endogenous glucose production
FFM Fat-free mass
GIP Glucose-dependent insulinotropic polypeptide
GLP Glucagon-like peptide
ISR Insulin secretion rate
PC Prohormone convertase
TCF7L2 Transcription factor 7-like 2
Introduction
Several studies have reported a link between variants in the
TCF7L2 gene and type 2 diabetes [1–8] and in a recent
meta-analysis, rs7903146 of TCF7L2 was associated with
type 2 diabetes with allelic odds ratios of 1.46, making it
the single strongest known genetic risk factor for type 2
diabetes [9].
TCF7L2 is expressed in the pancreatic beta cell, and
there is evidence of reduced insulin secretion in carriers of
the rs7903146 risk T allele [2, 10–12]. It has been
suggested that the association with type 2 diabetes may be
mediated through defects in the enteroinsular axis [3, 12,
13]. TCF7L2 encodes a transcription factor that binds to the
promoter of the proglucagon gene, which in turn encodes
glucagon, glucagon-like peptide (GLP)-1 and GLP-2 [14].
Inappropriately increased glucagon secretion is a described
abnormality in individuals with type 2 diabetes [15].
However, it is unknown whether this abnormality is present
in prediabetic patients or whether it may be secondary to
the diabetic state as such. Reduced secretion of GLP-1 and
impaired insulinotropic effect of GLP-1 and glucose-
dependent insulinotropic polypeptide (GIP) have been
reported in type 2 diabetes patients [16–18]. Interestingly,
Schafer et al. recently reported normal GLP-1 secretion but
reduced effect of GLP-1 upon stimulation of insulin
secretion in rs7903146 T allele carriers [12]. However, the
extent to which GIP secretion or action is influenced by
TCF7L2 variants is unknown. Lyssenko et al. [11] found
that basal endogenous glucose production (EGP) was
elevated in CT/TT carriers of rs7903146 of TCF7L2 in
the face of normal fasting plasma glucagon levels and that
rs7903146 had no impact on peripheral insulin action. It is
not known whether rs7903146 influences the suppressive
effect of insulin on hepatic glucose production. Finally, no
data are available addressing the impact of the TCF7L2
genotype on 24 h profiles of plasma glucose, insulin and
glucagon.
In this study we performed detailed metabolic character-
isation of young healthy glucose-tolerant men with and
without the TCF7L2 rs7903146 risk T alleles. We investigated
24 h profiles of plasma insulin, plasma glucagon and plasma
glucose and performed euglycaemic–hyperinsulinaemic
clamps combined with [3H]glucose tracer infusions to study
peripheral insulin action and hepatic glucose production. We
studied the secretion of GLP-1 and GIP during a meal test
and the action of the incretin hormones during a mild
hyperglycaemic clamp (7 mmol/l) with infusion of either
GLP-1 or GIP. Finally, we analysed fasting proglucagon and
glucagon levels to explore whether TCF7L2 genotype
influences alpha cell function.
Methods
Participants DNA was collected from 81 healthy white
men aged 18 to 23 years. All participants are participating in
a large-scale ongoing study programme aimed at determin-
ing the impact of the intrauterine environment and low
birthweight on development of type 2 diabetes later in life,
and have been extensively metabolically characterised [19,
20]. Consequently, half of the participants had birthweights
below the 10th percentile (2,800–3,010 g) and the other half
had birthweights in the upper normal range (3,390–4,300 g).
All participants were born at term and none had parents,
grandparents or siblings with any type of diabetes; none was
receiving medication known to interfere with glucose
homeostasis. Freathy et al. [21] found each risk allele of
the rs7903146 variant to be associated with an increase in
birthweight by 18 g, which was subsequently explained by
maternal hypoinsulinaemia and hyperglycaemia in pregnancy
and consequently increased offspring birthweight. Since
birthweight was an original inclusion variable, this was
adjusted for in all analyses. The protocol was approved by
the regional ethics committee and procedures were performed
according to the principles of the Helsinki Declaration. After
thorough written and oral explanation of the study all
participants gave their written consent.
Experimental protocols Detailed descriptions of the study
procedures have previously been provided [19, 20]. All 81
participants underwent standard blood testing after an
overnight fast (serum triacylglycerol, serum LDL- and
HDL-cholesterol, serum alanine transaminase, serum
thyroid-stimulating hormone, haemoglobin), anthropometric
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measurements, blood pressure and a dual-energy X-ray
absorptiometry scan. In addition, 34 of the 81 participants
underwent the four following tests after a 10 h fast:
1. 24 h profiles of plasma glucose, plasma insulin and
plasma glucagon. Blood samples were collected at
predefined time points (08:00, 09:45, 10:45, 12:45,
16:30, 18:30, 23:00, 03:00 and 08:00 hours) throughout
the 24 h period. Standardised meals were served at
08:15, 11:15, 17:00 and 20:30 hours. A light bicycle
exercise was performed at 10:00 and 13:00 hours.
2. OGTT. A standard 2 h 75 g OGTT was performed.
Blood samples for glucose were drawn at: 0, 30, 60, 90
and 120 min. Insulin, C-peptide, GLP-1 and GIP were
assessed at 0, 30 and 120 min.
3. IVGTT. A 30 min IVGTT was performed. At −1 min a
bolus of 0.3 g/kg glucose was given. Blood samples for
glucose, insulin and C-peptide were drawn at 0, 2, 4, 6,
8, 10, 15, 20 and 30 min.
4. Euglycaemic–hyperinsulinaemic clamps. A primed-
continuous infusion of [3-3H]glucose (bolus 40.3 KBq,
0.403 KBq/min) was initiated at 0 h. A primed-
continuous insulin infusion (square wave bolus 2 IU,
10 mU m−2 min−1) was begun at 150 min, continued for
120 min and increased to 40 mU m−2 min−1 for another
120 min. Steady state was defined as the last 30 min of
each 2 h basal, low-insulin and high-insulin clamp
period. Variable infusion of glucose (180 g/l) enriched
with [3H]glucose (50.9 KBq/500 ml [10 mU m−2 min−1],
203.5 KBq/500 ml [40 mU m−2 min−1]) was used to
maintain euglycaemia during insulin infusion.
Forty-seven of the 81 participants underwent the following
three tests after a 10 h fast: (1) a 2 h standardised mixed meal
tolerance test (2,370 kJ), with plasma being drawn for glucose,
insulin, C-peptide, GLP-1 and GIP determination at 0, 15, 30,
45, 60, 75, 90, 105 and 120 min; (2) hyperglycaemic clamps
(7mmol/l; 2 h) in conjunctionwith primed continuous infusion
of either GLP-1 or GIP, performed on separate days. Glucose
infusion was initiated at −30 min and terminated at 120 min.
At −2 min, a bolus of either GLP-1 or GIP was infused to
increase the plasma concentration to approximately 120 and
1,000 pmol/l, respectively. At 0 min, a continuous infusion of
GLP-1 (60 pmol kg−1 h−1) or GIP (240 pmol kg−1 h−1) was
initiated and terminated at 120. For these experiments
synthetic GLP-1 and GIP were purchased, dissolved and
dispensed as previously described [20]. The peptides were
more than 97% pure and identical to the natural human
peptides by HPLC, mass and sequence analysis.
Analytical procedures Plasma glucose, plasma insulin and
plasma C-peptide were determined as previously described
[19, 20]. Serum total proinsulin concentrations were
measured using two-site enzyme-linked immuno adsorbent
assay (sandwich ELISA) with monoclonal antibodies [22].
The assay shows 0% cross-reactivity with insulin and
C-peptide. Between-batch CVs were 0.0474 at 2.3 pmol/l,
0.067 at 5.1 pmol/l and 0.087 at 10 pmol/l. Blood for
analysis of plasma GLP-1 and plasma GIP was sampled in
heparin-EDTA tubes with addition of aprotinin, immediately
cooled on ice and centrifuged at 4°C for 20 min. Plasma was
stored at −20°C until analysis. Plasma samples were assayed
for GLP-1 immunoreactivity using a radioimmunoassay
specific for amidated C-terminus of the GLP-1 molecule.
Intact, biologically active GIP was measured using a newly
developed assay specific for the intact N-terminus of GIP.
This assay cross-reacts less than 0.1% with GIP(3-42) or
with the structurally related peptides GLP-1(7-36) amide,
GLP-1(9-36) amide, GLP-2(1-33) and GLP-2(3-33) or
glucagon at concentrations of up to 100,000 pmol/l.
Glucagon concentrations were measured after extraction of
plasma with 70% ethanol (vol./vol., final concentration). The
antibody employed (code no. 4305) was directed against the
C-terminus of the glucagon molecule and therefore mainly
measured glucagon of pancreatic origin [23]. A detailed
description of the analysis of glucagon, GLP-1 and GIP is
provided in Electronic supplementary material (ESM).
Statistical methods The effect of TCF7L2 rs7903146
genotype on various outcomes was evaluated by linear
regression analysis and data were adjusted for birthweight
and sampling period. Neither correction for birthweight nor
sampling period had a significant impact on the results. All
variables were checked for normal distribution and if
necessary logarithmically transformed prior to analysis. Tables
show means±SEM values unless otherwise indicated. A
p<0.05 (two-tailed analysis) was considered to be statistically
significant. Due to a relatively low number of individuals,
homozygous and heterozygous carriers of the T allele were
pooled in the analysis and a dominant model was applied.
Calculations The AUC was calculated by the trapezoidal
method during 24 h study, OGTT and IVGTT. Basal and
insulin-stimulated glucose turnover rates, including disposal
rates (Rd), glycolytic flux, glucose oxidation, glucose
storage and EGP were measured during euglycaemic–
hyperinsulinaemic clamp. Detailed information on these
calculations is provided in the ESM. During euglycaemic–
hyperinsulinaemic clamp the insulin sensitivity index (SiRd)
was defined as (Rd 40 mU−Rd basal)/(plasma insulin40 mU−
plasma insulinbasal)× (plasma glucose40 mU) (mg [kg
FFM]−1 min−1 [pmol/l insulin]−1 [mmol/l glucose]−1),
where FFM denotes fat-free mass. In the IVGTT, insulin
secretion rates (ISR) were calculated using the 0, 2, 4, 6,
8 and 10 min concentrations after initiation of the glucose
bolus. We used clamp-based estimate of insulin sensitivity
(SiRd) to calculate disposition indices during the IVGTT,
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namely: Di IVGTT (AUCISR 0–10/AUCglu 0–10)×SiRd (mg [kg
FFM]−1 min −1 [mmol/l glucose]−2); and during the OGTT:
Di OGTT ([AUCins/AUCglu]×SiRd) (mg [kg FFM]
−1 min−1
[mmol/l glucose]−2). During the meal test, AUCs were
calculated for plasma glucose, GLP-1 and GIP. ISRs were
estimated by deconvolution of the measured C-peptide
concentrations by applying population-based individual
variables for C-peptide kinetics and expressed as picomoles
per kilogram body weight, as described previously [24, 25].
Changes in ISR in response to changes in plasma glucose
during the meal test express the efficacy by which changes
in plasma glucose concentrations, amino acids and gut
factors (i.e. GLP-1 and GIP) stimulate insulin secretion.
Therefore, the relationship between plasma glucose con-
centrations and ISRs during the meal test was evaluated by
cross-correlation analyses in each patient. The relationship
was linear in all participants and the slope of the line was
used as an index (β-index) of beta cell response to glucose
(and incretin hormones). The β-index was not corrected for
differences in BMI, since body weight was accounted for
when calculating ISR. The combined smoothing and
deconvolution method may induce a tendency to flatten
rapid peaks in secretion resulting in early rise and delayed
decrease. For hyperglycaemic clamps with co-infusion of
GLP-1 or GIP, the first-phase insulin response was defined
as ISR AUC 0–20 min and the second-phase response as
ISR AUC 20–120 min.
Genotyping TCF7L2 rs7903146 was genotyped using
allelic discrimination performed with an ABI 7900 system
(KBioscience, Hoddesdon, UK). The genotype distribution
obeyed Hardy–Weinberg equilibrium (p>0.05). The minor
allele frequency of rs7903146 was 27.2% (95% CI 20.3–
34.2] with a genotype frequency for CC, CT and TT of
54%, 37% and 9% respectively. The overall genotyping
success rate was >96%.
Results
Characteristics of study participants As shown in Table 1,
the T allele of rs7903146 was significantly associated with
elevated HbA1c, reduced fasting insulin and higher proin-
sulin/insulin ratio, whereas fasting plasma glucose levels
were not significantly different. Fasting plasma glucagon
was reduced in the sample of 34 participants but not
significantly reduced in the combined group (n=81) of T
allele carriers.
Variables CC (n=44) CT or TT (n=37) p value
Anthropometry
Height (cm) 180.9±1.0 182.4±1.1 0.32
Weight (kg) 78.1±1.61 74.9±1.75 0.20
BMI (kg/m2) 23.8±0.4 22.7±0.5 0.06
Waist (cm) 83.3±1.19 81.4±1.31 0.29
Hip (cm) 98.3±0.99 96.6±1.09 0.25
WHR 0.85±0.0068 0.84±0.0074 0.64
Birthweight (g) 3,489±82 3,180±99 0.02
Fasting values
HbA1c (%) 5.17±0.04 5.31±0.05 0.05
Plasma glucose (mmol/l) 5.59±0.057 5.63±0.062 0.66
Plasma insulin (pmol/l) 44.1±3.2 31.4±2.6 0.003
Plasma proinsulin (pmol/l) 7.53±0.64 7.03±0.68 0.60
Ratioproinsulin/insulin 0.17±0.01 0.22±0.02 0.01
Plasma glucagon (ng/l) 43.6±2.20 39.4±2.34 0.23
Plasma proglucagon (pmol/l) 40.2±1.71 38.1±1.83 0.42
Ratioproglucagon/glucagon 3.33±0.11 3.43±0.11 0.56
Serum triacylgycerol (mmol/l) 1.18±0.12 0.96±0.13 0.21
Serum total cholesterol (mmol/l) 3.91±0.12 3.88±0.13 0.88
Serum HDL-cholesterol (mmol/l) 1.23±0.046 1.2±0.05 0.64
Serum LDL-cholesterol (mmol/l) 2.13±0.09 2.25±0.1 0.42
DEXA
Fat (%) 22.38±1.05 21.6±1.07 0.61
Total fat mass (g) 17,869±1195 16,457±1212 0.42
Total lean mass (g) 56,913±972 54,461±986 0.09
Table 1 Characteristics of
study participants
Values are means±SEM.
p values have been adjusted for
birthweight
DEXA, dual-energy x-ray
absorptiometry
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24 h profiles Figure 1 shows that while no effect of genotype
was observed on plasma glucose concentrations, plasma insulin
(AUCins 24 h: CT/TT: 1,752±202 vs CC: 2,314±182 pmol
l−1 day−1; p<0.05) and plasma glucagon (AUCglucagon 24 h:
CT/TT: 523±49 vs CC: 694±45 ng l− day−1; p<0.02)
concentrations were significantly reduced in T allele carriers.
Euglycaemic–hyperinsulinaemic clamp Glucose turnover
rates were evaluated in the basal state, and at 10 and
40 mU m−2 min−1 of insulin administration. As seen in
ESM Table 2, glucose disposal rates increased with
increasing plasma insulin levels, independently of geno-
type. Plasma glucose and plasma insulin levels were similar
between genotypes during the three steady-state periods
(ESM Fig. 1). By contrast, EGP was elevated at all three
physiological insulin levels in risk T allele carriers, reaching
significance at the basal state (EGPbasal CT/TT: 3.08±0.14
vs CC: 2.76±0.09 mg [kg FFM]−1 min−1; p<0.05) and
during the high insulin clamp where glucose production in
T allele carriers was twice that of wild-type participants
(EGP40 mU; CT/TT: 1.84±0.31 vs CC: 0.87±0.28 mg [kg
FFM]−1 min−1; p<0.03). Plasma glucagon was lower in T
allele carriers during the basal period (ESM Fig. 1). Basal
and insulin-stimulated glucose storage as well as the insulin
sensitivity index and glucose oxidation, non-oxidative
glucose metabolism and fat oxidation were similar in the
two genotype groups during all experimental settings (ESM
Table 2). The difference in BMI between genotype groups
in this cohort was 0.2 kg/m2. Correcting for this variable
had no influence on the results.
OGTT Plasma glucose concentrations during the OGTT
were identical in the two genotype groups (Fig. 2). A trend
towards lower plasma insulin levels was observed in risk
allele carriers at all time points (AUCins 0–120 CT/TT:
24,968±7,373 vs CC: 39,386±6,623 pmol l−1 [120 min]−1;
p=0.16) while disposition index did not differ (Di OGTT CT/
TT: 5.7×10−10±9.1×10−11 vs CC: 5.5×10−10±8.3×10−11
p=0.73). GLP-1 and GIP concentrations did not differ
between genotypes (AUC GLP-10–120 CT/TT: 2,577±326
vs CC: 3,086±293, pmol l−1 [120 min]−1; p=0.26; AUC
GIP0–120 CT/TT: 3,842±346 vs CC: 3,896±323 pmol l
−1
[120 min]−1; p=0.91).
IVGTT There were no significant differences in plasma
glucose or in first or late phase of insulin secretion between
genotypes (Fig. 3). Di did not differ between genotypes
(CT/TT: 0.84±0.09 vs CC: 0.66±0.07; p=0.11). The
overall insulin response in carriers of the T allele was
reduced during the OGTT compared with the IVGTT
(AUCinsOGTT/AUCinsIVGTT CT/TT: 1.45±0.16 vs CC:
2.00±0.22; p=0.06), supporting an imbalanced enteroinsu-
lar axis. To quantify the incretin abnormality, we compared
the ratio of AUCinsulin OGTT 0–30−AUCinsulin IVGTT 0–30/
AUCinsulin OGTT 0–30 [11] between genotypes. This surro-
gate marker of incretin effect was insignificantly decreased
in carriers of the risk T allele (CC: 2.00±0.22 vs CT/TT:
1.45±0.16; p=0.15).
Meal test ISRs (Fig. 4) mirrored the changes in plasma
glucose concentrations and returned to near fasting levels
after 90 min in both genotype groups. Both incretin
hormones exhibited prolonged profiles that did not reach
fasting levels at 120 min. Neither glucose levels nor ISR
differed significantly between genotype groups. Notably,
when expressed as beta cell responsiveness to changes in
glucose (β-index), i.e. the slope of the relationship between
the calculated ISR and the corresponding blood glucose
concentrations, carriers of the at-risk T allele had signifi-
cantly reduced postprandial beta cell responsiveness (CT/
TT: 2.85±0.29 vs CC: 4.15±0.27 pmol insulin kg−1 min−1
[mmol glucose]−1 l−1; p<0.003) even after accounting for
insulin sensitivity (HOMA-IR); (p<0.006). There was a
trend towards reduced postprandial secretion of GIP in risk
allele carriers (CT/TT: 5583±470 vs CC: 6691±462 pmol
l−1 [120 min]−1; p=0.086) only reaching significance at
45 min (CT/TT: 46±4 vs CC: 61±5 pmol l−1; p=0.035).
GLP-1 concentrations did not differ significantly between
genotypes.
Hyperglycaemic clamps with co-infusion of GLP-1 or
GIP The first-phase insulin response (0–20 min) was
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similar between risk allele carriers and non-carriers during
GLP-1 as well as during GIP infusion (Fig. 5). In contrast,
the ISRs were significantly reduced in carriers of the T
allele during GLP-1 infusion at 75 and 90 min, and overall
in the late phase (AUC20–120 CT/TT: 1,068±79 vs CC:
1,323±78; p=0.03). During infusion of GIP, ISRs were
significantly reduced at 15, 60 and 65 min and also tended to
be reduced during the late phase of GIP infusion (AUC20–120
CT/TT: 630±36 vs CC: 722±33; p=0.07), indicating
reduced insulinotropic effects of both GLP-1 and GIP.
Prohormones To address the hypothesis of malfunctioning
prohormone convertase (PC) 1 and 2 in risk allele carriers,
we performed post hoc analysis of the prohormones in the
fasting state in all 81 individuals (Table 1). While plasma
proinsulin levels were similar, plasma insulin was decreased
and consequently the ratio of proinsulin:insulin increased in
carriers of the risk T allele (CT/TT: 0.22±0.02 vs CC: 0.17±
0.01; p=0.014). However, the ratio of proglucagon/glucagon
was not clearly affected by genotype (CT/TT: 3.44±0.12 vs
CC: 3.25±0.11; p=0.259).
Discussion
The novel findings in this study include reduced insulino-
tropic effect of GLP-1 as well as reduced beta cell
responsiveness to glucose during a meal test in risk allele
carriers of TCF7L2 rs7903146 among 47 young glucose-
tolerant Danish men. In a similar group of 34 young healthy
men, carriers of the risk T allele were characterised by
elevated endogenous (hepatic) glucose production (EGP) as
well as reduced 24 h circulating plasma insulin and plasma
glucagon levels.
The major strength of this study is the detailed and
extensive in vivo physiological phenotyping of a homozygous
group of young white men, allowing us to document a number
of metabolic abnormalities linking carriers of the T allele of
0
2
4
6
8
10
0 30 60 90 120
G
lu
co
se
 (m
mo
l/l)
a
0
100
200
300
400
500
600
In
su
lin
 (p
mo
l/l)
b
0
5
10
15
20
25
30
35
40
G
LP
-1
 (p
mo
l/l)
c
0
10
20
30
40
50
G
IP
 (p
mo
l/l)
d
Time (min)
0 30 60 90 120
Time (min)
0 30 60 90 120
Time (min)
0 30 60 90 120
Time (min)
Fig. 2 OGTT. a Plasma glucose
(p=0.57 for AUC); b plasma
insulin (p=0.15 for AUC);
c GLP-1 (p=0.26 for AUC); and
d GIP (p=0.91 for AUC). Data
presented as mean±SEM,
p values are corrected for birth-
weight. No significant differ-
ence was seen at any time point.
Broken lines with white
triangles, risk T allele carriers
(n=15); continuous lines with
black circles, wild-type
participants (n=19)
0
5
10
15
20
25
30
35
IS
R 
(pm
ol 
kg
–
1  
m
in
–
1 )
b
0
4
8
12
16
20
0 5 10 15 20 25 30
P-
gl
uc
os
e 
(m
mo
l/l)
a
0
100
200
300
400
500
Time (min)
0 5 10 15 20 25 30
Time (min)
0 5 10 15 20 25 30
Time (min)
0 5 10 15 20 25 30
Time (min)
In
su
lin
 (p
mo
l/l)
c
0.0
0.5
1.0
1.5
2.0
2.5
3.0
C-
pe
pt
id
e 
(nm
ol/
l)
d
Fig. 3 IVGTT. a Plasma (P)
glucose (p=NS for AUC);
b ISRs (p=NS for AUC); c
P-insulin (p=NS for AUC); and
d plasma C-peptide (p=NS for
AUC). Data presented as
mean±SEM, p values are
corrected for birthweight.
Broken lines with white trian-
gles, risk allele carriers (n=15);
continuous lines with black
circles, wild-type participants
(n=19)
Diabetologia (2009) 52:1298–1307 1303
rs7903146 to increased risk of type 2 diabetes. Conversely, an
evident weakness is the relatively low number of study
participants when seen in a genetic and epidemiological
perspective.
Reduced insulin secretion associated with TCF7L2
polymorphisms may be mediated through multiple different
mechanisms. Transcription factor 7-like 2 (TCF7L2) is
present in human islet cells [11, 26, 27] and animal studies
have found that it directly regulates insulin secretion [27].
TCF7L2 operates in conjunction with β-catenin as a
transcription factor to activate the expression of wingless-
type MMTV integration site family member 2 (WNT)-
signalling target genes. The WNT signalling pathway is
involved in cell differentiation, beta cell proliferation [28]
and insulin secretion [29]. The proglucagon gene is
transcriptionally regulated by TCF7L2 and proglucagon is
processed to GLP-1 in the L-cells of the intestines. Besides
its insulinotropic effect, recent studies have shown that
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GLP-1 induces Wnt signalling in the beta cell and that
WNT signalling appears to mediate GLP-1-induced beta
cell proliferation [30]. Two studies have already provided
evidence of an incretin-mediated insulin secretion defect in
carriers of the risk allele [11, 12]. Our data expand on
current knowledge by unmasking a robust early-onset beta
cell hypo-responsiveness to GLP-1 in a young, healthy,
glucose-tolerant population at much lower plasma glucose
(7 mmol/l) using high physiological GLP-1 levels. Further-
more, we found a borderline significant reduction of insulin
secretion during hyperglycaemic clamps with co-infusion
of GIP in carriers of the risk T allele. Our differential
findings of reduced late-, but not initial-phase insulin
secretion in the carriers of the T alleles in response to both
incretin hormones indicate that the acute release of insulin
from the readily releasable granules docked on or in close
proximity to the plasma membrane is intact, while the
subsequent second phase of insulin release primarily
derived from stored secretory granules and de novo insulin
synthesis is impaired during GLP-1, and to some extent
also GIP administration. The extent to which the impaired
insulinotropic effect of GLP-1 may be due to acute intrinsic
abnormalities, central effects or even mediated through
reduced beta cell proliferation very early in life remains to
be elucidated.
Theoretically, insulin secretion should be corrected for in
vivo insulin sensitivity by calculating the disposition index,
thereby accounting for the inverse relationship between
insulin secretion and action in non-diabetic participants.
Interestingly, the sensitivity and responsiveness of pancreatic
insulin secretion to glucose during meal tests (i.e. the beta
index) remained significantly reduced after correction for
insulin action in carriers of the T allele of rs7903146
TCF7L2, supporting the notion of a true functional defect
of pancreatic insulin secretion.
Most studies of patients with overt type 2 diabetes report
elevated plasma glucagon levels compared with non-
diabetic controls [15, 31]. Thus, our finding of lower, and
not of elevated plasma glucagon levels during 24 h profiles in
carriers of the T allele genotype may appear somewhat
paradoxical. On the other hand TCF7L2 is also a transcription
factor of the proglucagon gene and proglucagon is processed
to glucagon in alpha cells [32]. Reduced expression of
proglucagon in the alpha cells or altered posttranslational
processing to glucagon could explain our findings of reduced
plasma glucagon levels during 24 h profiles. Furthermore, it
is possible that the apparent insulin secretion defect may be
enhanced by impaired paracrine glucagon stimulation of the
beta cells [33, 34]. Finally, the novel idea that TCF7L2 is
involved in the control of plasma glucagon levels is
supported by unpublished data (V. Lyssenko and L. Groop)
from 580 non-diabetic individuals participating in the
Prevalence–Prediction–Prevention study, in which two other
single nucleotide polymorphisms of TCF7L2, including
rs10885414 and rs4639863 (but not rs7903146), were
associated with altered plasma glucagon levels (p=0.03 and
p=0.02, respectively).
Two other recent studies reported a disproportionately
increased basal rate of EGP and hepatic insulin resistance in
carriers of the risk T allele of rs7903146 [11, 35].
Expanding on those recent findings, we found the absolute
rate of EGP to be elevated in the basal state as well as
during a high physiological insulin infusion in carriers of
the risk T allele. While the elevated basal rate of EGP may
be due to relatively lower endogenous ‘portal’ insulin
secretion, this may not explain the elevated rate of EGP
during clamp insulin infusions. Notably, the reduced
diurnal plasma glucagon profiles were found in exactly
the same participants with a documented elevated rate of
EGP, so the increased EGP was not driven by elevated
plasma glucagon levels. Studies in two MODY genotypes,
HNF-1α/β (also known as HNF1A/B), have reported
differential effects of HNF-1β and HNF-1α on hepatic
insulin sensitivity, with normal plasma glucagon levels and
unaffected peripheral insulin sensitivity, and it has been
proposed that the site of defect is located in the regulation
of insulin action by HNF-1β and its effect on gluconeo-
genesis [36]. Intra-cerebral administration of a GLP-1
receptor agonist caused a fourfold increase in insulin
secretion and enhanced liver glycogen storage in mice
[37]. It remains to be determined whether TCF7L2 exerts a
direct or indirect (via the central nervous system) influence
on hepatic gluconeogenesis, glycogenolysis and/or glycogen
synthesis, explaining its effect on EGP in the basal state as
well as during insulin infusion.
In accordance with findings from Loos et al. [10], we
found an increased ratio of proinsulin/insulin, which was
primarily due to relatively reduced insulin levels as
opposed to elevated proinsulin levels as such. We saw no
impact of genotype on the proglucagon/glucagons ratio.
PC1 and PC2 are differentially synthesised in various
endocrine cell lines and give rise to a varied mixture of
peptide products [38]. It can be hypothesised that carriers of
the risk T allele have a specific impairment in PC1, which is
more greatly involved in post-translational insulin processing
than PC2, which has been shown to account for the majority
of proglucagon processing in the alpha cells [39]. GLP-1 is
processed from proglucagon by PC1 in the L-cells. Schäfer
et al. reported unaffected levels of GLP-1 in response to an
OGTT in risk allele carriers [12]. In this study, GLP-1 levels
were non-significantly lower in carriers of the T allele of the
TCF7L2 genotype, and additional studies will be required to
provide conclusive results concerning the impact of this
genotype on GLP-1 secretion.
In conclusion, we report that in two populations of young,
healthy, glucose-tolerant men, carriers of the risk T allele of
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rs7903146 TCF7L2 had significantly elevated HbA1c as well
as reduced fasting/postabsorptive and postprandial insulin
concentrations during the course of a standardised 24 h period.
The T allele was associated with reduced beta cell responsive-
ness to a mixed meal and diminished incretin effect as
evidenced by reduced late-phase beta cell responsiveness to
GLP-1. The finding of elevated EGP in the basal state and
during insulin infusion in the face of paradoxically reduced
plasma glucagon levels in carriers of the T allele indicates
either a more direct role of TCF7L2 in the regulation of hepatic
glucose metabolism or a potential indirect effect on hepatic
glucose metabolism operating via the central nervous system.
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